OTCMKTS:DTCFF Defence Therapeutics (DTCFF) Stock Price, News & Analysis $0.52 -0.04 (-7.73%) As of 07/3/2025 10:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Defence Therapeutics Stock (OTCMKTS:DTCFF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Defence Therapeutics alerts:Sign Up Key Stats Today's Range$0.52▼$0.5250-Day Range$0.52▼$0.7652-Week Range$0.27▼$1.16Volume800 shsAverage Volume15,603 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Read More Receive DTCFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DTCFF Stock News HeadlinesDefence Therapeutics Inc.April 30, 2025 | barrons.comDefence Therapeutics Inc (DTC.DU)February 9, 2025 | ca.finance.yahoo.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now. | Porter & Company (Ad)Defence Therapeutics Secures $3.9 Million to Boost Biotech InitiativesJanuary 31, 2025 | tipranks.comDefence Therapeutics Strengthens Patent Portfolio, Secures Market ExclusivityJanuary 7, 2025 | markets.businessinsider.comDefence Therapeutics Strengthens Leadership with Key AppointmentsDecember 20, 2024 | markets.businessinsider.comDefence Therapeutics to License Accum TechnologyNovember 29, 2024 | tipranks.comDefence Therapeutics Welcomes Radiopharmaceutical ExpertNovember 14, 2024 | markets.businessinsider.comSee More Headlines DTCFF Stock Analysis - Frequently Asked Questions How have DTCFF shares performed this year? Defence Therapeutics' stock was trading at $0.3901 on January 1st, 2025. Since then, DTCFF stock has increased by 32.4% and is now trading at $0.5166. How do I buy shares of Defence Therapeutics? Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:DTCFF CIKN/A Webdefencetherapeutics.com Phone514 947 2272FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:DTCFF) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Defence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DTCFF Stock Alerts